Spironolactone was first developed as a medication for blood pressure and heart failure. It also has anti-androgenic properties that make it effective for treating conditions driven by androgen activity in women — including androgenetic alopecia. It is not FDA-approved for hair loss, but it is one of the most widely prescribed off-label treatments for female pattern hair loss, with a growing body of evidence supporting its use. This article explains how spironolactone works for hair loss, what the clinical evidence shows, and who is most likely to benefit.
How Spironolactone Works as an Anti-Androgen
Spironolactone blocks the androgen receptor: the receptor that DHT and testosterone bind to in order to produce their effects on target tissues, including hair follicles. By occupying the receptor without activating it, spironolactone competitively inhibits androgen signaling. This means DHT can still be present, but its ability to bind to the follicle androgen receptor and trigger miniaturization is reduced.
Spironolactone also reduces androgen synthesis. It inhibits several enzymes involved in the production of testosterone and DHT, including CYP17A1, which is expressed in the adrenal glands and other tissues. This gives it a twofold mechanism: reduced androgen production and reduced androgen receptor sensitivity.
Spironolactone addresses androgenetic alopecia through a different mechanism than finasteride and dutasteride. Those drugs reduce DHT production; spironolactone blocks DHT's ability to act on the androgen receptor, while also reducing production.
Why Spironolactone Is Used Specifically in Women
Spironolactone is not used in men with hair loss for two reasons. First, its androgen receptor blockade and anti-androgenic effects cause feminizing side effects in men — including gynecomastia, reduced libido, and sexual dysfunction — that are not acceptable in most male patients. Second, eplerenone (a related drug without anti-androgenic activity) can be substituted for spironolactone's cardiovascular applications when these side effects are unwanted.
In women, the anti-androgenic profile is therapeutically useful rather than problematic. Women with androgenetic alopecia driven by androgen sensitivity benefit directly from reduced androgen receptor activity at the follicle.
Spironolactone is reserved for women in hair loss treatment because its anti-androgenic side effects are unacceptable in men. In women with androgenetic alopecia, those same effects are the therapeutic mechanism. Clinical Evidence
The evidence base for spironolactone in female pattern hair loss consists primarily of retrospective studies, open-label trials, and clinical case series rather than large randomized controlled trials. This reflects its prevalent clinical use before systematic trial data existed, as well as the challenges of conducting large RCTs in off-label prescribing.
A 2009 retrospective study by Sinclair and colleagues reviewed outcomes in 40 women with female pattern hair loss treated with spironolactone 200 mg daily. At 12 months, 44% showed improvement in hair density, 44% remained stable, and only 12% continued to worsen. The stabilization rate — 88% combined improvement or stability — is significant.
A 2017 retrospective study of 100 women treated with spironolactone 50–200 mg daily found that 74% showed improvement in hair density at 12 months, assessed by global photographic comparison.
Similarly, a 2023 randomized controlled trial of spironolactone versus minoxidil in women with female pattern hair loss enrolled 100 participants over 24 weeks. Both groups showed significant hair density improvement, with no statistically significant difference between them — suggesting spironolactone produces outcomes comparable to 5% minoxidil in women with female pattern hair loss.
The evidence supports spironolactone as an effective treatment for female pattern hair loss, with clinical response rates comparable to minoxidil in available comparative data.
Dosing and Practical Considerations
Standard doses for hair loss in clinical practice range from 50 mg to 200 mg daily. Many clinicians start at 50–100 mg and titrate upward based on response and tolerability over 3 to 6 months.
The onset of action is slow. Meaningful improvement typically requires 6 to 12 months of consistent treatment.
Spironolactone requires monitoring because of its effects on blood potassium. At higher doses, it can cause hyperkalemia (elevated potassium) which affects cardiac function. Electrolyte monitoring at baseline and periodically during treatment is standard practice.
For women who are or may become pregnant, spironolactone is contraindicated. It is teratogenic, and reliable contraception is required during use.
Spironolactone requires baseline labs, electrolyte monitoring, and contraception in women of reproductive age. These are manageable requirements that do not prevent its clinical use. Side Effects
Common side effects at typical doses include:
Menstrual irregularity: Most common side effect at higher doses. Usually improves with dose adjustment or resolves with time.
Breast tenderness: Reported in a subset of users, typically transient.
Increased urination: Reflects its diuretic mechanism. Usually modest at hair loss doses.
Dizziness or lightheadedness: More common with higher doses, particularly on standing.
Serious adverse effects are uncommon at the doses used for hair loss (50–200 mg daily) compared to the higher doses used for cardiovascular indications, but monitoring remains important.
Side effects are generally manageable at hair loss doses. Menstrual irregularity is the most commonly reported concern and often responds to dose adjustment.
Combining Spironolactone With Minoxidil
Many clinicians combine spironolactone with topical or oral minoxidil for women with androgenetic alopecia. The rationale is the same as for combination therapy in men: spironolactone addresses the androgen receptor pathway while minoxidil addresses the follicle environment and growth stimulation. Each drug contributes through a different mechanism.
Published data on the combination is limited compared to data on each agent alone, but clinical experience supports the approach, particularly for women with significant or rapidly progressing loss.
Spironolactone plus minoxidil addresses both the androgenic driver and the follicle growth environment in women, using the same complementary logic as finasteride plus minoxidil in men. Summary
Spironolactone is one of the most widely used treatments for female pattern hair loss. It works by blocking the androgen receptor and reducing androgen synthesis, reducing the androgenic drive on hair follicles. Clinical studies show meaningful improvement in hair density in the majority of treated women. It requires monitoring for potassium and is contraindicated in pregnancy. Side effects are generally manageable at hair loss doses. It can be combined with minoxidil for better outcomes and is a well-supported option for women with androgenetic alopecia who are not candidates for or prefer not to use finasteride.